Search results for "Neoplasms"

showing 10 items of 7988 documents

Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations.

2017

Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineSurgical oncologyCeliac ArteryInternal medicinemedicineHumansYoung adultCystadenocarcinomaSurvival rateLymph nodeAgedRetrospective StudiesOvarian Neoplasmsbusiness.industryLiver NeoplasmsRetrospective cohort studyCytoreduction Surgical ProceduresMiddle Agedmedicine.diseaseovarian cancer hepatoceliac lymph nodes metastasesPrognosisCystadenocarcinoma SerousEndometrial NeoplasmsSurvival Rate030104 developmental biologymedicine.anatomical_structureSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisSurgery; OncologyAdenocarcinomaLymph Node ExcisionSurgeryFemaleLymph NodesbusinessAdenocarcinoma Clear CellFollow-Up StudiesAnnals of surgical oncology
researchProduct

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

2021

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Mei…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMultivariate analysisNeutrophilsQH301-705.5medicine.medical_treatmentBreast NeoplasmsArticleDisease-Free Survivalpredictive/prognostic biomarkers03 medical and health sciences0302 clinical medicineText miningBreast cancerluminal breast cancerInternal medicineMedicineHumansLymphocytesNeutrophil to lymphocyte ratioBiology (General)Neoadjuvant therapyAgedRetrospective StudiesChemotherapybusiness.industryProportional hazards modelallergologyfungiLuminal breast cancer; Neoadjuvant chemotherapy; Neutrophil to lymphocyte ratio (NLR); Predictive/prognostic biomarkers; Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Lymphocytes; Middle Aged; Multivariate Analysis; Neutrophils; Prognosis; Retrospective Studies; Treatment Outcome; Neoadjuvant TherapyHistologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisneutrophil to lymphocyte ratio (NLR)Neoadjuvant Therapy030104 developmental biologyKi-67 AntigenTreatment Outcome030220 oncology & carcinogenesisMultivariate AnalysisPopulation studyFemalebusinessneoadjuvant chemotherapy
researchProduct

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

2017

Abstract Purpose Visceral metastasis of breast cancer (BC) is an alarming development and correlates with poor median overall survival. The purpose of this retrospective study is to examine the risk factors for developing visceral metastasis by considering tumor biology and patient characteristics. Methods Using the BRENDA database, the risk factors such as histological and intrinsic subtypes of BC, age at primary diagnosis, grading, nodal status, tumor size and year of primary diagnosis were examined in univariate and multivariate analysis. Categorical variables were compared by using χ2 tests. Furthermore, multivariate Cox proportional hazards regression models, Kaplan–Meier product-limit…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyMultivariate statisticsMultivariate analysisLung NeoplasmsBreast NeoplasmsKaplan-Meier EstimateLogistic regressionMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsInternal medicineMedicineHumansGrading (tumors)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCarcinoma Ductal BreastLiver NeoplasmsUnivariateAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyLogistic Models030220 oncology & carcinogenesisMultivariate AnalysisSurgeryFemalebusinessBreast (Edinburgh, Scotland)
researchProduct

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemothera…

2016

Abstract Background The recommendation for adjuvant dose-dense chemotherapy in high risk primary breast cancer is heterogeneous among guidelines. Understanding the impact on QoL is thereby a crucial factor, especially if the benefit is potentially low. This study aims to assess QoL as a secondary outcome in the prospective randomized multi-center ADEBAR trial. Methods QoL was assessed at baseline (t1), before cycle 4 FEC and cycle 5 EC-DOC (t2), 4 weeks after chemotherapy (t3) and 6 weeks after radiation (t4) using the European Organization for Research and Treatment for Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Breast Cancer-Specific Module (QLQ-BR23). Results 130…

0301 basic medicineOncologyAdultmedicine.medical_specialtyTime FactorsAdolescentNauseamedicine.medical_treatmentBreast NeoplasmsDocetaxelDrug Administration Schedule03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideAgedEpirubicinChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseasehumanitiesSurgery030104 developmental biologyTreatment OutcomeDocetaxelFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeSurgeryFemaleTaxoidsFluorouracilmedicine.symptombusinessmedicine.drugEpirubicinBreast (Edinburgh, Scotland)
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Monoclonal antibodies for the treatment of non-hematological tumors: a safety review

2018

Introduction: The introduction of monoclonal antibodies (moAbs) into clinical practice revolutionized the treatment strategies in several solid tumors. These agents differ from cytotoxic chemotherapy for their mechanism of action and toxicity. By targeting specific antigens present on healthy cells and modulating immune system activity, these biological drugs are able to generate a wide spectrum of peculiar adverse events that can negatively impact on patients' quality of life. Areas covered: In this review, the main side effects associated with the use of moAbs have been described to show their incidence and current management strategies, which may drive clinicians in their daily practice.…

0301 basic medicineOncologyAdverse eventPD-L1medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentEGFRMonoclonal antibody03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Immune systemAntineoplastic Agents ImmunologicalInternal medicinePD-L1NeoplasmsPD-1medicineAnimalsHumansPharmacology (medical)Precision MedicineAdverse effectbiologybusiness.industrytarget therapymoAbsCancerAntibodies MonoclonalmoAbGeneral MedicineImmunotherapymedicine.diseaseVEGFSurvival Rate030104 developmental biologyCTLA-4HER-2030220 oncology & carcinogenesisAdverse eventsbiology.proteinQuality of LifeCTLA-4Adverse events; CTLA-4; EGFR; HER-2; immunotherapy; moAbs; PD-1; PD-L1; target therapy; VEGF; Pharmacology (medical)immunotherapybusiness
researchProduct

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

2018

Abstract Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established…

0301 basic medicineOncologyCancer ResearchAdoptive cell transfermedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCell- and Tissue-Based TherapyReceptors Antigen T-CellApoptosisReceptors Cell SurfaceTriple Negative Breast NeoplasmsTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerAntigenInternal medicineBiomarkers TumorTumor Cells CulturedMedicineAnimalsHumansTriple-negative breast cancerCell Proliferationbusiness.industryMicrofilament ProteinsCancerImmunotherapyTriple Negative Breast Neoplasmsmedicine.diseasePrognosisXenograft Model Antitumor AssaysNeoplasm ProteinsSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisCase-Control StudiesFemaleImmunotherapybusinessFollow-Up StudiesCancer research
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct